Pharmacogenetic Testing: Time for Clinical Practice Guidelines

被引:35
|
作者
Amstutz, U. [1 ,2 ,3 ]
Carleton, B. C. [1 ,2 ,3 ]
机构
[1] Univ British Columbia, Dept Pediat, Fac Med, Vancouver, BC V6T 1W5, Canada
[2] BC Childrens Hosp, Pharmaceut Outcomes Programme, Vancouver, BC, Canada
[3] Child & Family Res Inst, Vancouver, BC, Canada
关键词
BREAST-CANCER RECURRENCE; CONCURRENT USE; TAMOXIFEN; THERAPY; UPDATE; CYP2D6; WOMEN;
D O I
10.1038/clpt.2011.18
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Our knowledge regarding genetic factors that affect drug effectiveness and adverse drug reactions is continuously increasing, and a growing number of pharmacogenetic gene-drug interactions are included in drug labels. Nevertheless, the uptake of this important information into clinical practice has been minimal. The development of concise, evidence-based clinical practice guidelines (CPGs) on pharmacogenetic testing is urgently needed to overcome the barriers hindering clinical implementation by providing guidance on test use and interpretation.
引用
收藏
页码:924 / 927
页数:4
相关论文
共 50 条
  • [21] Time to move beyond clinical practice guidelines?
    Pain, CH
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2001, 175 (05) : 287 - 287
  • [22] Implementing clinical practice guidelines: time to assess it
    Sessa, Cristiana
    Colombo, Nicoletta
    Creutzberg, Carien L.
    Concin, Nicole
    Wimberger, Pauline
    Curigliano, Giuseppe
    Marinoni, Klizia
    Douillard, Jean-Yves
    Pentheroudakis, George
    Torri, Valter
    Rauh, Stefan
    [J]. ESMO OPEN, 2020, 5 (06)
  • [23] RANZCP clinical practice guidelines - time to digitise
    Lugg, William
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2021, 55 (11): : 1114 - 1116
  • [24] Asthma clinical practice guidelines: Time for an update
    Ballas, Zuhair K.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 142 (03) : 787 - 787
  • [25] Pharmacogenetic Information in Clinical Guidelines: The European Perspective
    Swen, Jesse J.
    Nijenhuis, Marga
    van Rhenen, Mandy
    de Boer-Veger, Nienke J.
    Buunk, Anne-Marie
    Houwink, Elisa J. F.
    Mulder, Hans
    Rongen, Gerard A.
    van Schaik, Ron H. N.
    van der Weide, Jan
    Wilffert, Bob
    Deneer, Vera H. M.
    Guchelaar, Henk-Jan
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 795 - 801
  • [26] Clinical and regulatory considerations in pharmacogenetic testing
    Schuck, Robert N.
    Marek, Elizabeth
    Rogers, Hobart
    Pacanowski, Michael
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (23) : 1999 - 2006
  • [27] Pharmacogenetic testing and antidepressants: A clinical perspective
    Jagadheesan, Karuppiah
    Tipirneni, Surya
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2021, 294 : 448 - 449
  • [28] Pharmacogenetic testing in the UK clinical setting
    Bartlett, Mark J.
    Green, David W.
    Shephard, Elizabeth A.
    [J]. LANCET, 2013, 381 (9881): : 1903 - 1903
  • [29] Clinical pharmacy consultation for pharmacogenetic testing
    Shin, Jaekyu
    Kayser, Steven R.
    [J]. PERSONALIZED MEDICINE, 2009, 6 (02) : 183 - 192
  • [30] Pharmacogenetic dose recommendations in clinical practice
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    [J]. EJHP PRACTICE, 2011, 17 (05): : 28 - 29